PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
16959960-7	2006	In addition, the combination of sorafenib and rottlerin reduced or completely inhibited the phosphorylation of extracellular signal-regulated kinase and Akt and down-regulated cell cycle regulatory proteins such as cyclin-D1, cyclin-D3, cyclin-dependent kinase (cdk)4, and cdk6 in a dose- and time-dependent manner.	Sorafenib	32-41	cyclin dependent kinase 4	Homo sapiens	237-267	
30962952-6	2019	Copanlisib strongly reduced cell viability and colony formation in different native and sorafenib-resistant HCC cell lines by affecting cyclin D1/CDK4/6 signaling and causing cell cycle arrest.	Sorafenib	88-97	cyclin dependent kinase 4	Homo sapiens	146-152	
32306906-0	2020	Modulation of SIRT3 expression through CDK4/6 enhances the anti-cancer effect of sorafenib in hepatocellular carcinoma cells.	Sorafenib	81-90	cyclin dependent kinase 4	Homo sapiens	39-45	
30292139-5	2018	Mechanism dissection suggests that the combination of MLN8237 and sorafenib led to significant inhibition of the activation of phospho-Akt (p-Akt) and phospho-p38 mitogen-activated protein kinase (p-p38 MAPK) and their downstream genes including CDK4, cyclinD1, and VEGFA.	Sorafenib	66-75	cyclin dependent kinase 4	Homo sapiens	246-250	
20950443-5	2010	RESULTS: Sorafenib inhibited the proliferation of ALL cells by cell cycle arrest accompanied by down-regulation of CyclinD3 and CDK4.	Sorafenib	9-18	cyclin dependent kinase 4	Homo sapiens	128-132	
28855436-6	2017	Sorafenib inhibited constitutive activation of the MAPK pathway, cyclin-dependent kinase 4 (CDK4), and phosphorylated retinoblastoma protein (RB) in 3 well-differentiated carcinoma cell lines, but it did not show sufficiently effective suppression of cell growth.	Sorafenib	0-9	cyclin dependent kinase 4	Homo sapiens	65-90	
28855436-6	2017	Sorafenib inhibited constitutive activation of the MAPK pathway, cyclin-dependent kinase 4 (CDK4), and phosphorylated retinoblastoma protein (RB) in 3 well-differentiated carcinoma cell lines, but it did not show sufficiently effective suppression of cell growth.	Sorafenib	0-9	cyclin dependent kinase 4	Homo sapiens	92-96